KR101450653B1 - 비스테로이드 항염증제의 황화수소 유도체 - Google Patents

비스테로이드 항염증제의 황화수소 유도체 Download PDF

Info

Publication number
KR101450653B1
KR101450653B1 KR1020097001029A KR20097001029A KR101450653B1 KR 101450653 B1 KR101450653 B1 KR 101450653B1 KR 1020097001029 A KR1020097001029 A KR 1020097001029A KR 20097001029 A KR20097001029 A KR 20097001029A KR 101450653 B1 KR101450653 B1 KR 101450653B1
Authority
KR
South Korea
Prior art keywords
compound
phenyl
mmol
compounds
diclofenac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097001029A
Other languages
English (en)
Korean (ko)
Other versions
KR20090036115A (ko
Inventor
존 엘. 월러스
쥬세페 치리노
빈센초 산타가다
쥬세페 카리엔도
Original Assignee
안티브 홀딩스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안티브 홀딩스 인크. filed Critical 안티브 홀딩스 인크.
Publication of KR20090036115A publication Critical patent/KR20090036115A/ko
Application granted granted Critical
Publication of KR101450653B1 publication Critical patent/KR101450653B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
KR1020097001029A 2006-07-18 2007-07-18 비스테로이드 항염증제의 황화수소 유도체 Active KR101450653B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80763906P 2006-07-18 2006-07-18
US60/807,639 2006-07-18
US88718807P 2007-01-30 2007-01-30
US60/887,188 2007-01-30
PCT/CA2007/001289 WO2008009127A1 (en) 2006-07-18 2007-07-18 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs

Publications (2)

Publication Number Publication Date
KR20090036115A KR20090036115A (ko) 2009-04-13
KR101450653B1 true KR101450653B1 (ko) 2014-10-14

Family

ID=38956479

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097001029A Active KR101450653B1 (ko) 2006-07-18 2007-07-18 비스테로이드 항염증제의 황화수소 유도체
KR1020097001128A Expired - Fee Related KR101495520B1 (ko) 2006-07-18 2007-07-18 약제의 4-하이드록시티오벤즈아미드 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097001128A Expired - Fee Related KR101495520B1 (ko) 2006-07-18 2007-07-18 약제의 4-하이드록시티오벤즈아미드 유도체

Country Status (17)

Country Link
US (1) US8314140B2 (https=)
EP (2) EP2041108B1 (https=)
JP (2) JP5529534B2 (https=)
KR (2) KR101450653B1 (https=)
AU (2) AU2007276679B2 (https=)
BR (2) BRPI0714330A2 (https=)
CA (2) CA2658429A1 (https=)
DK (1) DK2057139T3 (https=)
ES (1) ES2437223T3 (https=)
IL (2) IL196229A (https=)
MX (2) MX2009000749A (https=)
NO (2) NO20090764L (https=)
NZ (1) NZ573996A (https=)
PL (1) PL2057139T3 (https=)
PT (1) PT2057139E (https=)
RU (2) RU2468019C2 (https=)
WO (2) WO2008009118A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
DK2057139T3 (da) * 2006-07-18 2013-11-18 Antibe Holdings Inc Hydrogensulfidderivater af non-steroide anti-inflammatoriske lægemidler
ITMI20080382A1 (it) * 2008-03-07 2009-09-08 Ctg Pharma S R L Composizioni farmaceutiche oculari
ITMI20081167A1 (it) * 2008-06-26 2009-12-27 Ctg Pharma S R L Composizioni farmaceutiche per il trattamento di malattie neurodegenerative
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
WO2011053597A1 (en) * 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US9242009B2 (en) 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
AU2017263574B2 (en) 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2019094772A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
JP2021066660A (ja) * 2018-02-09 2021-04-30 アピオン・ジャパン有限会社 Ｔｉｒａｐ阻害剤
WO2022115952A1 (en) * 2020-12-03 2022-06-09 Antibe Therapeutics Inc. [1-(4-chloro-benzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-acetic acid 4-thiocarbamoyl-phenyl ester for the treatment of a viral infection
WO2023159296A1 (en) * 2022-02-28 2023-08-31 Antibe Therapeutics Inc. 4-thiocarbamoylphenyl 2-(4-oxophenyl)-phenyl propanoate for the treatment of pain associated with urologic chronic pelvic pain syndrome
GR1010438B (el) * 2022-03-21 2023-04-06 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Φαρμακευτικες ενωσεις που βασιζονται στο συνδυασμο ενος ανταγωνιστη της ισταμινης και ενος δοτη υδροθειου για χρηση στην αντιμετωπιση του κνησμου
WO2025076616A1 (en) * 2023-10-11 2025-04-17 Antibe Therapeutics Inc. Polymorphic forms of otenaproxesul and compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037623A2 (en) * 2004-10-07 2006-04-13 Ctg Pharma S.R.L. New nuclear transcription factors regulators
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
KR20090040428A (ko) * 2006-07-18 2009-04-24 안티브 테라퓨틱스 인크. 약제의 4-하이드록시티오벤즈아미드 유도체

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612252A (https=) * 1961-01-05
US4170654A (en) * 1976-02-13 1979-10-09 Merck & Co., Inc. Antihypertensive compositions containing N-heterocyclicalanines and α-
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US5214191A (en) * 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
US5663416A (en) * 1990-05-22 1997-09-02 Cortech Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US7638513B2 (en) * 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
EP1630164A1 (en) * 2004-08-31 2006-03-01 Expotrend Company SA Pyrazolopyrimidinones as phosphodiesterase inhibitors
CN2757375Y (zh) * 2004-11-25 2006-02-08 富士康(昆山)电脑接插件有限公司 电子卡连接器
CA2601381A1 (en) 2005-03-24 2006-09-28 Nycomed Gmbh 6-thioamide substituted benzimidazoles
ITMI20050680A1 (it) * 2005-04-18 2006-10-19 Ctg Pharma S R L Nuovi composti anti-infiammatori
US7498355B2 (en) 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037623A2 (en) * 2004-10-07 2006-04-13 Ctg Pharma S.R.L. New nuclear transcription factors regulators
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
KR20090040428A (ko) * 2006-07-18 2009-04-24 안티브 테라퓨틱스 인크. 약제의 4-하이드록시티오벤즈아미드 유도체

Also Published As

Publication number Publication date
EP2041108A1 (en) 2009-04-01
HK1131973A1 (en) 2010-02-12
JP2009543813A (ja) 2009-12-10
NO20090764L (no) 2009-04-16
BRPI0714466B8 (pt) 2021-05-25
PL2057139T3 (pl) 2014-06-30
AU2007276621A1 (en) 2008-01-24
AU2007276621B2 (en) 2013-08-01
WO2008009118A1 (en) 2008-01-24
RU2009105498A (ru) 2010-08-27
AU2007276679B2 (en) 2013-05-30
MX2009000750A (es) 2009-01-30
PT2057139E (pt) 2013-12-05
IL196229A (en) 2016-04-21
KR101495520B1 (ko) 2015-02-26
NZ573996A (en) 2012-03-30
CA2658429A1 (en) 2008-01-24
EP2057139B1 (en) 2013-09-04
BRPI0714466A2 (pt) 2013-05-14
DK2057139T3 (da) 2013-11-18
ES2437223T3 (es) 2014-01-09
MX2009000749A (es) 2009-01-30
BRPI0714330A2 (pt) 2013-05-07
CA2658433C (en) 2015-04-28
KR20090036115A (ko) 2009-04-13
EP2057139A1 (en) 2009-05-13
RU2009105491A (ru) 2010-08-27
IL196228A0 (en) 2009-09-22
JP2009543811A (ja) 2009-12-10
JP5529534B2 (ja) 2014-06-25
BRPI0714466B1 (pt) 2020-09-24
EP2057139A4 (en) 2010-09-15
NO342083B1 (no) 2018-03-19
RU2465271C2 (ru) 2012-10-27
KR20090040428A (ko) 2009-04-24
EP2041108A4 (en) 2010-12-29
RU2468019C2 (ru) 2012-11-27
AU2007276679A1 (en) 2008-01-24
HK1131125A1 (en) 2010-01-15
JP5408719B2 (ja) 2014-02-05
US8314140B2 (en) 2012-11-20
CA2658433A1 (en) 2008-01-24
WO2008009127A1 (en) 2008-01-24
NO20090763L (no) 2009-04-03
IL196229A0 (en) 2009-09-22
US20090306412A1 (en) 2009-12-10
EP2041108B1 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
KR101450653B1 (ko) 비스테로이드 항염증제의 황화수소 유도체
US7741359B2 (en) Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
JP3880067B2 (ja) 新規化合物並びに抗炎症及び抗血栓活性を有する組成物
KR101298880B1 (ko) 4- 또는 5-아미노살리실산의 유도체
ES2296616T3 (es) Composiciones farmaceuticas.
RU2136653C1 (ru) Нитроэфиры, обладающие противовоспалительной и/или анальгетической активностью, способы их получения, фармацевтические композиции
JPH09512798A (ja) 消炎、鎮痛および抗血栓活性を有するニトロ化合物およびそれらの組成物
CN101490029B (zh) 药物的4-羟基硫代苯甲酰胺衍生物
CA2608627A1 (en) Novel nsaids possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety
EP0017543B1 (fr) Dérivés du benzothiazole, leur procédé de préparation et leurs applications en thérapeutique
HK1131973B (en) Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
SU1634134A3 (ru) Способ получени 4-оксо-4-(замещенный фенил)-бутеноилсалицилатов Е-конфигурации
HK1131125B (en) 4-hydroxythiobenzamide derivatives of drugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120709

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130830

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140623

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130830

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140718

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140623

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101004427

Request date: 20140718

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140814

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140718

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140129

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20140917

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20140826

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141007

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141008

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170828

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170828

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180830

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180830

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190930

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190930

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210923

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220927

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20231004

Start annual number: 10

End annual number: 10